SCHEMBL31667736

SCHEMBL31667736

O=C1c2ccccc2[C@H](C2CC2)N1Cc1ccc2[nH]c(=O)oc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IL4I1 Q96RQ9 1/20 0.43
▸ MAPT P10636 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ LMNA P02545 3/20 0.43
▸ HPGD P15428 2/20 0.42
▸ MAPK1 P28482 4/20 0.39
▸ TSHR P16473 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ OGT O15294 1/20 0.39
▸ GRIN1 Q05586 3/20 0.39
▸ MDM2 Q00987 3/20 0.38
▸ GRIN2D O15399 1/20 0.38
▸ GRIN3B O60391 1/20 0.38
▸ GRIN2A Q12879 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38
▸ GRIN2C Q14957 1/20 0.38
▸ GRIN3A Q8TCU5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31666945 1.00 IL4I1 (0.43) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667320 1.00 IL4I1 (0.43) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667224 0.84 IL4I1 (0.44) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667081 0.84 MEN1 (0.41) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31666976 0.84 IL4I1 (0.46) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667642 0.84 IL4I1 (0.46) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667115 0.84 IL4I1 (0.46) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667679 0.83 MEN1 (0.45) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667717 0.83 MEN1 (0.45) IL4I1MAPTMEN1KMT2ALMNA
SCHEMBL31667345 0.83 IL4I1 (0.45) IL4I1MAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 — — US disclosed
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 IL4I1 2872/4885MAPT 523/4885MEN1 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback